CVS Health price target lowered to $80 from $100 at Argus

Argus lowered the firm’s price target on CVS Health to $80 from $100 but keeps a Buy rating on the shares. The analyst cites the company reporting Q1 earnings “well below expectations” as CVS is seeing higher-than-expected usage in the Medicare Advantage plans it sells in the Health Care Benefits business. Argus adds however that it still “sees value” in CVS Health shares.